Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 15/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.74 |
| ▸ | HPGD | P15428 | 12/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Visnadine SCHEMBL12710639 | 1.00 | KDM4E (0.74) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Visnadine SCHEMBL30640212 | 1.00 | KDM4E (0.74) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL31153360 | 0.90 | KDM4E (0.76) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Seravshanin SCHEMBL30565432 | 0.86 | KDM4E (0.76) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Dihydrosamidin SCHEMBL12062121 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| Suksdorfin SCHEMBL15532093 | 0.83 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL4759420 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL30517506 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL29785360 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 | |
| SCHEMBL30350458 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1HPGDCYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1606 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117224417-A | Repairing and anti-aging preparation containing nucleic acid extracting stock solution and preparation method | 海南宜含实业投资有限公司 | 2023-12-15 | — | — | CN | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| EP-4188362-A1 | GYNAECOLOGICAL COMPOSITIONS BASED ON CANNABIDIOL AND TERPENES IN COMBINATION WITH PERIPHERAL VASODILATORS | Agora' Pharma S.r.l. (IT) | 2023-06-07 | — | — | EP | claimed |
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-03-23 | — | — | US | claimed |
| US-20220339259-A1 | ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF | SHEN HAIFA (US) | 2022-10-27 | — | — | US | claimed |
| CN-114466658-A | Orally delivered therapeutic compositions and uses thereof | 沈海发 | 2022-05-10 | — | — | CN | claimed |
| US-11324748-B2 | Vasodilators for treatment of heart failure | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-05-10 | — | — | US | claimed |
| WO-2022029813-A1 | GYNAECOLOGICAL COMPOSITIONS BASED ON CANNABIDIOL AND TERPENES IN COMBINATION WITH PERIPHERAL VASODILATORS | AGORA' PHARMA S.R.L. (IT) | 2022-02-10 | — | — | WO | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| US-10738068-B2 | Organic/inorganic hybrid nanoparticulates made from iron carboxylates | Centre National de la Recherche Scientifique—CNRS (FR) | 2020-08-11 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000057836-A2 | COSMETIC OR DERMATOLOGICAL COMPOSITIONS CONTAINING AT LEAST ONE SUBSTANCE FOR INCREASING THE FUNCTIONALITY AND/OR EXPRESSION OF CD44 MEMBRANE RECEPTORS OF SKIN CELLS | PARFUMS CHRISTIAN DIOR (FR) | 2000-10-05 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999062481-A1 | COSMETIC TREATMENT METHOD FOR FIGHTING AGAINST SKIN AGEING EFFECTS | GUERLAIN S.A. (FR) | 1999-12-09 | — | — | WO | claimed |
| US-5795575-A | Topical medicament which increases the number of capillaries in damaged skin | INDENA S.P.A. (IT) | 1998-08-18 | — | — | US | claimed |
| WO-1997042928-A1 | TOPICAL SLIMMING COMPOSITION | LVMH RECHERCHE (FR) | 1997-11-20 | — | — | WO | claimed |
| EP-0680761-A1 | Topical medicament having cicatrizing activity | INDENA S.p.A. (IT) | 1995-11-08 | — | — | EP | claimed |
| EP-0418806-B1 | Pharmaceutical compositions havin activity on the cutaneous microcirculation | INDENA SPA (IT) | 1994-01-05 | — | — | EP | claimed |
| US-5176919-A | Ammi plant extracts, visnadine, topical, vasodilator effect | INDENA, S.P.A. (IT) | 1993-01-05 | — | — | US | claimed |
| EP-0418806-A1 | Pharmaceutical compositions havin activity on the cutaneous microcirculation | INDENA S.p.A. (IT) | 1991-03-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | VASP, TNNI3, EDNRB | KDM4E 4093/4885ALDH1A1 1929/4885HPGD 74/4885 |
| US-10738068-B2 | Organic/inorganic hybrid nanoparticulates made from iron carboxylates | SLC40A1, FECH, FTH1 | KDM4E 2603/4885ALDH1A1 301/4885HPGD 822/4885 |
| US-20220339259-A1 | ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF | FABP2, SLC27A1, SLC27A2 | KDM4E 2382/4885ALDH1A1 3875/4885HPGD 4622/4885 |
| US-11324748-B2 | Vasodilators for treatment of heart failure | VASP, TNNI3, EDNRB | KDM4E 4093/4885ALDH1A1 1929/4885HPGD 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.